Merus N.V. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
13,154.00
23,092.10
25,709.20
52,243.50
82,439.60
28,631.30
Depreciation, Depletion & Amortization
350.50
335.60
214.00
258.90
358.70
Other Funds
-
-
61.00
-
126,320.80
Funds from Operations
12,515.50
22,523.00
24,866.40
26,669.30
38,017.00
Changes in Working Capital
3,388.10
3,268.40
617.70
1,699.10
3,134.50
Net Operating Cash Flow
9,127.40
19,254.70
25,484.10
28,368.40
41,151.60
Capital Expenditures
110.20
208.30
114.20
548.70
816.60
Purchase/Sale of Investments
-
-
-
-
47,181.50
Net Investing Cash Flow
110.20
208.30
114.20
548.70
47,998.10
Issuance/Reduction of Debt, Net
221.70
221.50
8,687.30
184.70
762.50
Net Financing Cash Flow
15,721.70
7,782.30
60,288.70
55,475.80
209,857.90
Net Change in Cash
6,484.10
11,680.70
34,690.40
26,565.30
104,440.00
Free Cash Flow
9,237.60
19,462.90
25,598.30
28,917.10
41,968.20
Change in Capital Stock
15,943.40
8,003.80
51,540.40
55,660.50
84,299.60
Exchange Rate Effect
-
-
-
6.60
16,268.20

About Merus

View Profile
Address
Yalelaan 62
Utrecht Utrecht 3584 CH
Netherlands
Employees -
Website http://www.merus.nl
Updated 07/08/2019
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.